These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39379505)

  • 21. Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy.
    Aziz I; McFarlane LC; Lipworth BJ
    Eur J Clin Pharmacol; 1998 Jul; 54(5):377-81. PubMed ID: 9754979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K; Janicki S; Jörres RA; Magnussen H
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta
    Hostrup M; Reitelseder S; Jessen S; Kalsen A; Nyberg M; Egelund J; Kreiberg M; Kristensen CM; Thomassen M; Pilegaard H; Backer V; Jacobson GA; Holm L; Bangsbo J
    J Physiol; 2018 Sep; 596(17):4121-4139. PubMed ID: 29968301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of inhaled salbutamol in exercising non-asthmatic athletes.
    Goubault C; Perault MC; Leleu E; Bouquet S; Legros P; Vandel B; Denjean A
    Thorax; 2001 Sep; 56(9):675-9. PubMed ID: 11514686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects.
    Midgren B; Melander B; Persson G
    Chest; 1992 Apr; 101(4):1019-22. PubMed ID: 1348219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta
    Hostrup M; Narkowicz CK; Habib S; Nichols DS; Jacobson GA
    Drug Test Anal; 2019 Jul; 11(7):1048-1056. PubMed ID: 30836453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.
    Haney S; Hancox RJ
    Respir Res; 2007 Mar; 8(1):19. PubMed ID: 17341317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes.
    Heir T; Stemshaug H
    Scand J Med Sci Sports; 1995 Aug; 5(4):231-6. PubMed ID: 7552768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J; Ankerst J
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma.
    Ferrari M; Balestreri F; Baratieri S; Biasin C; Oldani V; Lo Cascio V
    Respiration; 2000; 67(5):510-3. PubMed ID: 11070454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
    Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
    Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Haney S; Hancox RJ
    Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
    Jonkers RE; Bantje TA; Aalbers R
    Respir Res; 2006 Dec; 7(1):141. PubMed ID: 17144916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
    Lipworth BJ; Aziz I
    J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
    van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
    Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The ergogenic effect of long-term use of high dose salbutamol.
    Dickinson J; Molphy J; Chester N; Loosemore M; Whyte G
    Clin J Sport Med; 2014 Nov; 24(6):474-81. PubMed ID: 24451697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of formoterol compared to salbutamol.
    Hekking PR; Maesen F; Greefhorst A; Prins J; Tan Y; Zweers P
    Lung; 1990; 168 Suppl():76-82. PubMed ID: 1974686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.